A database containing phenotypes from RNA interference (RNAi) screens in Drosophila and human. In addition, the database provides an updated resource of RNAi reagents and their predicted quality. RNAi screening data is extracted from the literature by manual curation, but we also provide a functionality for direct submission by data producers. The new version has undergone a complete re-design of the user interface, providing an intuitive, flexible framework for additional functionalities. Screen information and gene-reagent-phenotype associations are now available for download. The integration with other resources has been improved by allowing in-links via GenomeRNAi screen IDs, or external gene or reagent identifiers. A distributed annotation system (DAS) server enables the visualization of the phenotypes and reagents in the context of a genome browser.

User report

0 user reviews

0 user reviews

No review has been posted.

GenomeRNAi forum

No open topic.

GenomeRNAi classification

  • Animals
    • Drosophila melanogaster
    • Homo sapiens

GenomeRNAi specifications

Restrictions to use:
Data access:
File download, Web user interface
CC Attribution
User data submission:

GenomeRNAi support




  • (Schmidt et al., 2013) GenomeRNAi: a database for cell-based and in vivo RNAi phenotypes, 2013 update. Nucleic acids research.
    PMID: 23193271
  • (Gilsdorf et al., 2010) GenomeRNAi: a database for cell-based RNAi phenotypes. 2009 update. Nucleic acids research.
    PMID: 19910367
  • (Horn et al., 2007) GenomeRNAi: a database for cell-based RNAi phenotypes. Nucleic acids research.
    PMID: 17135194


Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ) and Department of Cell and Molecular Biology, Medical Faculty Mannheim, Heidelberg University, D-69120 Heidelberg, Germany

Funding source(s)

European Community’s Seventh Framework Programme [FP7/2007-2013] (CancerPathways); Helmholtz Alliance for Systems Biology

Link to literature

By using OMICtools you acknowledge that you have read and accepted the terms of the end user license agreement.